310 related articles for article (PubMed ID: 33012328)
21. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
[TBL] [Abstract][Full Text] [Related]
22. Biologics for asthma and allergy.
Walsh GM
Curr Opin Otolaryngol Head Neck Surg; 2017 Jun; 25(3):231-234. PubMed ID: 28234780
[TBL] [Abstract][Full Text] [Related]
23. The Use of Omalizumab in Food Oral Immunotherapy.
Labrosse R; Graham F; Des Roches A; Bégin P
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):189-199. PubMed ID: 27628022
[TBL] [Abstract][Full Text] [Related]
24. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
25. Updates on current evidence for biologics in chronic rhinosinusitis.
Nasta MS; Chatzinakis VA; Georgalas CC
Curr Opin Otolaryngol Head Neck Surg; 2020 Feb; 28(1):18-24. PubMed ID: 31789925
[TBL] [Abstract][Full Text] [Related]
26. Orphan immunotherapies for allergic diseases.
Ridolo E; Montagni M; Incorvaia C; Senna G; Passalacqua G
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):194-8. PubMed ID: 26837608
[TBL] [Abstract][Full Text] [Related]
27. Economic aspects of sublingual immunotherapy.
Incorvaia C; Ariano R; Berto P; Ciprandi G; Leo G; Boccardo R; Scurati S; Frati F
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):27-30. PubMed ID: 19944007
[TBL] [Abstract][Full Text] [Related]
28. Pet dander and difficult-to-control asthma: Therapeutic options.
Ling M; Long AA
Allergy Asthma Proc; 2010; 31(5):385-91. PubMed ID: 20929605
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
30. Biologics for Asthma and Allergic Skin Diseases in Children.
De Keyser HH; Chipps B; Dinakar C;
Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.
Tsabouri S; Tseretopoulou X; Priftis K; Ntzani EE
J Allergy Clin Immunol Pract; 2014; 2(3):332-40.e1. PubMed ID: 24811026
[TBL] [Abstract][Full Text] [Related]
32. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
33. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody therapy in sinonasal disease.
Chiarella SE; Sy H; Peters AT
Am J Rhinol Allergy; 2017 Mar; 31(2):93-95. PubMed ID: 28281440
[TBL] [Abstract][Full Text] [Related]
35. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review.
Lin SY; Erekosima N; Kim JM; Ramanathan M; Suarez-Cuervo C; Chelladurai Y; Ward D; Segal JB
JAMA; 2013 Mar; 309(12):1278-88. PubMed ID: 23532243
[TBL] [Abstract][Full Text] [Related]
36. Oral Immunotherapy for Peanut Allergy.
Anagnostou K; Clark A
Annu Rev Med; 2016; 67():375-85. PubMed ID: 26332004
[TBL] [Abstract][Full Text] [Related]
37. Undertreatment of allergy: exploring the utility of sublingual immunotherapy.
Emanuel IA; Parker MJ; Traub O
Otolaryngol Head Neck Surg; 2009 May; 140(5):615-21. PubMed ID: 19393398
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous injection immunotherapy for optimal effectiveness.
Nelson HS
Immunol Allergy Clin North Am; 2011 May; 31(2):211-26, viii. PubMed ID: 21530815
[TBL] [Abstract][Full Text] [Related]
39. Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
Owens G; Petrov A
Curr Drug Saf; 2011 Nov; 6(5):339-42. PubMed ID: 22424542
[TBL] [Abstract][Full Text] [Related]
40. House dust mite-specific immunotherapy alters the natural course of atopic march.
Tang RB
J Chin Med Assoc; 2020 Feb; 83(2):109-112. PubMed ID: 32015265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
